Prot #AVXS-101-CL-303: A Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1 with One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion (STRIVE)

Project: Research project

Project Details

StatusFinished
Effective start/end date5/2/18 → 5/2/21

Funding

  • Ann & Robert H. Lurie Children's Hospital of Chicago (Prot #AVXS-101-CL303 // Prot #AVXS-101-CL303)
  • AveXis, Inc. (Prot #AVXS-101-CL303 // Prot #AVXS-101-CL303)